Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia
Brain, 10/30/2009
|
Compta Y et al. – Excessive daytime sleepiness is more frequent in Parkinson's disease patients with dementia than Parkinson's disease patients without dementia, but lumbar cerebrospinal fluid hypocretin ... status. Lumbar cerebrospinal fluid does not accurately reflect the hypocretin cell loss known to occur in the hypothalamus of advanced Parkinson's disease. Alternatively, mechanisms other than hypocretin cells dysfunction may be responsible for excessive daytime sleepiness and the sleep architecture
[more...]
|
Sleep disturbances in Malaysian patients with Parkinson's disease using polysomnography and PDSS
Parkinsonism & Related Disorders, 10/29/2009
|
Norlinah MI et al. – The prevalence of sleep disorders based on polysomnography (PSG) and Parkinson's disease sleep scale (PDSS) in these Parkinson's disease (PD) patients was high, the commonest
[more...]
|
Effects of optimism/pessimism and locus of control on disability and quality of life in Parkinson's disease
Parkinsonism & Related Disorders, 10/29/2009
|
Gruber–Baldini AL et al. – Low optimism or high pessimism is associated with reduced quality of life in Parkinson's disease. Patients with less internal locus of control have greater disability ... assist in reducing disability and improving quality of life in Parkinson's disease.
[more...]
|
Condition Raises Parkinsons Risk 5-Fold
Ivanhoe, 10/27/2009
|
face a five–fold risk of developing Parkinson's disease. Parkinson's disease, a neurological condition that causes tremors and stiffness in movement, affects 1 to 2 percent of people over the age of 60. The chance of developing Parkinson's disease increases with age and involves a combination
[more...]
|
Markers of neurodegeneration in idiopathic rapid eye movement sleep behaviour disorder and Parkinson's disease
Brain, 10/30/2009
|
Postuma RB et al. – Patients with idiopathic rapid eye movement sleep behaviour disorder demonstrate abnormalities in numerous potential markers of neurodegenerative disease—these ... abnormalities are usually intermediate between control values and Parkinson's patients, autonomic dysfunction and colour vision appear to be more linked to rapid eye movement sleep behaviour disorder status than Parkinson's disease, suggesting a unique pathophysiology of these abnormalities
[more...]
|
An evaluation of self-administration of auditory cueing to improve gait in people with Parkinson's disease
Clinical Rehabilitation, 11/18/2009
|
Bryant MS et al. – The aim is to evaluate a self–administration of auditory cueing on gait difficulties in people with Parkinson’s disease over a one–week period. Gait performance in people with Parkinson’s disease improved significantly
[more...]
|
The effect of eating utensil weight on functional arm movement in people with Parkinson's disease: a controlled clinical trial
Clinical Rehabilitation, 11/18/2009
|
Ma H–I et al. – The findings suggest that a lightweight utensil may facilitate smoother and higher–velocity arm movement than a weighted one in people with Parkinson’s disease.
[more...]
|
Widely Used Cholesterol-lowering Drug May Prevent Progression Of Parkinsons Disease
ScienceDaily, 11/10/2009
|
Parkinson's is a slowly progressive disease that affects a small area of cells within the mid–brain known as the substantia nigra. Gradual degeneration of these cells causes a reduction in dopamine, which is ... the classic signs of Parkinson's disease that includes, resting tremor on one side of the body, generalized slowness of movement, stiffness of limbs, and gait or balance problems. The cause of Parkinson's disease is unknown. Both environmental and genetic causes of the disease have been postulated
[more...]
|
Novel agent for treatment of Parkinson's disease - Lu 02-750 - enters Lundbeck's development pipeline
Lundbeck, 11/02/2009
|
H. Lundbeck A/S strengthens its pipeline of pharmaceuticals in clinical development by initiating phase I clinical studies with Lu 02–750 in order to investigate safety, tolerability and the ... a dopaminergic agent acting on brain areas affected in Parkinson's disease. In animal models, the compound has demonstrated very convincing effects as compared to conventional treatments. Expectations are that the compound can offer Parkinson's patients a new and higher level of disease control
[more...]
|
GIGYF2 mutations are not a frequent cause of familial Parkinson's disease
Parkinsonism & Related Disorders, 11/09/2009
|
Di Fonzo A et al. – Mutations in the Grb10–interacting GYF protein 2 (GIGYF2) gene, within the PARK11 locus, have been nominated as a cause of Parkinson's disease in Italian and French populations. By sequencing ... probands (thirty–seven Italians) with familial Parkinson's disease compatible with an autosomal dominant inheritance, the authors identified no mutations. This data add to a growing body of evidence suggesting that GIGYF2 mutations are not a frequent cause of PD.
[more...]
|
